3 of 10 pregnant patients who continued imatinib experienced adverse issues.
ONCOLOGY
Fully funded by 
Content independently selected
-
CML: how much risk is associated with imatinib during pregnancy? -
CLL: 17-gene signature predicts durable remission with frontline FCR Signature validated in patients from the CLL8 study.
-
CML-CP: low-dose dasatinib delivers durable efficacy with good tolerability 95% achieved CCyR at 12 months of dasatinib 50 mg.
-
Consensus on donor lymphocytes in the management of leukaemia Expert recommendations commission by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
-
Early data support panobinostat benefit in high-risk AML More than 4 in 10 patients achieved complete remission.
-
We report a successful allogeneic transplantation and long-term engraftment of CRISPR–Cas9–edited stem cells in a patient with HIV and acute lymphoblastic leukemia.
-
3 predictors of fracture risk in survivors of childhood leukemia/lymphoma More than 1 in 10 aged 15-19 years at diagnosis had very low BMD.
-
Gilteritinib has been shown to improve overall survival compared to salvage chemotherapy in this patient group.
-
Pediatric AML: risk for cytogenetic abnormalities rises with BMI BMI was not associated with treatment-related or overall mortality.
-
R/R CLL: ibrutinib maintains efficacy advantage at 6 years Nearly 7 in 10 patients crossed over to ibrutinib.
-
Ibrutinib: invasive fungal disease more common than expected in CLL, NHL 69% all-cause mortality despite timely antifungal therapy.
-
Nilotinib shows efficacy in pediatric chronic-phase Ph+ CML One of the 2 studies that led to regulatory approval in the US.
-
Frontline CLL: obinutuzumab + chemotherapy manageable, efficacious in fit patients 64% of patients were MRD-negative in peripheral blood.
-
ALL: Ph-like subtype relatively prevalent, carries poorer prognosis 15-study meta-analysis finds survival similar to that of Ph-positive disease.